Pharmacological Therapies in Acne vulgaris

  • Tomás Esteves Caseiro Mendes de Freitas Mestre em Medicina - Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal
  • Glória Maria Cardoso da Cunha Velho Assistente Graduada de Dermatologia e Venereologia; Professora Auxiliar Convidada de Dermatologia da Unidade Curricular de Medicina I e Especialidades Médicas do Mestrado Integrado em Medicina no Instituto Ciências Biomédicas Abel Salazar/Centro Hospitalar do Porto, Porto, Portugal
Keywords: Acne Vulgaris/drug therapy, Administration, Cutaneous, Administration, Oral, Dermatologic Agents


Acne vulgaris is a chronic disease of the pilosebaceous unit characterized by cutaneous polymorphism, representing one of the most prevalent diseases in adolescence. It can lead to physical sequelae, such as disfiguring scars, and psychological, with a decreased quality of life and psychosocial function. Thus, an effective therapeutic strategy is essential in order to promote its resolution and minimize sequelae. Nowadays, there are several available drugs, but their choice requires biopsychosocial assessment of the patient. Recent studies have shown promising new therapeutic agents, as alternatives to topical retinoids, oral isotretinoin, oral antiandrogens, and antibiotics, which would allow a reduction in antibiotic resistance and a consequent increase in efficacy with a substantial reduction in adverse effects. Increasing security and tolerability of new drugs would improve the current approach of acne treatment.


Download data is not yet available.


Amer SS, Nasr M, Mamdouh W, Sammour O. Insights on the use of nanocarriers for acne alleviation. Curr Drug Deliv. 2019;16:18-25.

Becker M, Wild T, Zouboulis CC. Objective assessment of acne. Clin Dermatol. 2017;35:147–55.

Williams H C, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012;379: 361–72.

Kontochristopoulos G, Platsidaki E. Chemical peels in active acne and acne scars. Clin Dermatol. 2017;35:179–82.

Wolkenstein P, Machovcová A, Szepietowski JC, Tennstedt D, Veraldi S, Delarue A. Acne prevalence and associations with lifestyle: a cross-sectional online survey of adolescents/young adults in 7 European countries. J Eur Acad Dermatol Venereol. 2017;32:298–306.

Barnes LE, Levender MM, Fleischer AB, Feldman SR. Quality of Life Measures for Acne Patients. Dermatol Clin. 2012;30:293–300.

Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74:945–73.

Gieler U, Gieler T, Kupfer J. Acne and quality of life - impact and management. J Eur Acad Dermatol Venereol. 2015;29:12–4.

Revol O, Milliez N, Gerard D. Psychological impact of acne on 21st-century adolescents: decoding for better care. Br J Dermatol. 2015;172:52–8.

Jankovic S, Vukicevic J, Djordjevic S, Jankovic J, Marinkovic J, et al. Quality of life among schoolchildren with acne: Results of a cross-sectional study. Indian J Dermatol Venereol Leprol. 2012;78:454.

Tuchayi SM, Makrantonaki E, Ganceviciene R, Dessinioti C, Feldman SR, Zouboulis CC. Acne vulgaris. Nat Rev Dis Primers. 2015;15033.

Läuchli S. Acne Vulgaris. Curr Probl Dermatol. 2011;42:140–6.

Knutsen-Larson S, Dawson AL, Dunnick CA, Dellavalle RP. Acne Vulgaris: Pathogenesis, Treatment, and Needs Assessment. Dermatol Clin. 2012;30: 99–106.

Trivedi MK, Bosanac SS, Sivamani RK, Larsen LN. Emerging therapies for acne vulgaris. Am J Clin Dermatol. 2018;19:505–16.

Well D. Acne vulgaris. Nurse Pract. 2013;38:22–31.

Botros PA, Tsai G, Pujalte GG. Evaluation and management of acne. Prim Care. 2015;42, 465–471.

Kim RH, Armstrong AW. Current state of acne treatment: highlighting lasers, photodynamic therapy, and chemical peels. Dermatol Online J. 2011;17(3):2.

Das S, Reynolds RV. Recent advances in acne pathogenesis: implications for therapy. Am J Clin Dermatol. 2014;15: 479–88.

Dréno B. What is new in the pathophysiology of acne, an overview. J Eur Acad Dermatol Venereol. 2017;31: 8–12.

Dréno B, Gollnick HP, Kang S, Thiboutot D, Bettoli V, Torres V, et al. Understanding innate immunity and inflammation in acne: implications for management. J Eur Acad Dermatol Venereol. 2015;29: 3–11.

Suh DH, Kwon HH. What’s new in the physiopathology of acne? Br J Dermatol. 2015;172:13–9.

Smith EV, Grindlay DJ, Williams HC. What’s new in acne? An analysis of systematic reviews published in 2009-2010. Clin Exp Dermatol. 2011;36:119–22.

Taylor M, Gonzalez M, Porter R. Pathways to inflammation: acne pathophysiology. Eur J Dermatol. 2011;21: 323-33

Dréno B, Bettoli V, Araviiskaia E, Viera MS, Bouloc A. The influence of exposome on acne. J Eur Acad Dermatol Venereol. 2018;32:812–9.

Gollnick HP. From new findings in acne pathogenesis to new approaches in treatment. J Eur Acad Dermatol Venereol. 2015;29:1–7.

Goh CL, Abad-Casintahan F, Aw DC, Baba R, Chan LC, Hung NT et al. South-East Asia study alliance guidelines on the management of acne vulgaris in South-East Asian patients. J Dermatol. 2015;42:945–53.

Gollnick HP, Bettoli V, Lambert J, Araviiskaia E, Binic I, Dessinioti C, et al. A consensus-based practical and daily guide for the treatment of acne patients. J Eur Acad Dermatol Venereol. 2016;30:1480–90.

Kosmadaki M, Katsambas A. Topical treatments for acne. Clin Dermatol. 2017;35:173–8.

Simonart T. Newer approaches to the treatment of acne vulgaris. Am J Clin Dermatol. 2012;13:357–64.

Kolli SS, Pecone D, Pona A, Cline A, Feldman SR. Topical retinoids in acne vulgaris: a systematic review. Am J Clin Dermatol. 2019;20:345-65.

Imahiyerobo-Ip JI, Dinulos JG. Changing the topography of acne with topical medications. Curr Opin Pediatr. 2011;23:121–5.

Veraldi S, Barbareschi M, Benardon S, Schianchi R. Short contact therapy of acne with tretinoin. J Dermatolog Treat. 2013;24:374–6.

Hsu P, Litman GI, Brodell RT. Overview of the treatment of acne vulgaris with topical retinoids. Postgrad Med. 2011;123:153-61.

Leyden J. Recent advances in the use of adapalene 0.1%/benzoyl peroxide 2.5% to treat patients with moderate to severe acne. J Dermatolog Treat. 2016;27: S4–S13.

Gonzalez P, Vila R, Cirigliano M. The tolerability profile of clindamycin 1%/benzoyl peroxide 5% gel vs. adapalene 0.1%/benzoyl peroxide 2.5% gel for facial acne: results of a randomized, single-blind, split-face study. J Cosmet Dermatol. 2012;11:251–60.

Maiti R, Sirka CS, Ashique Rahman MA, Srinivasan A, Parida S, Hota D. Efficacy and Safety of Tazarotene 0.1% Plus Clindamycin 1% Gel Versus Adapalene 0.1% Plus Clindamycin 1% Gel in Facial Acne Vulgaris: A Randomized, Controlled Clinical Trial. Clin Drug Investig. 2017;37:1083–91.

Smith JA, Narahari S, Hill D, Feldman SR. Tazarotene foam, 0.1%, for the treatment of acne. Exp Opin Drug Saf. 2015;15:99–103.

Ahluwalia J, Borok J, Haddock ES, Ahluwalia RS., Schwartz EW, Hosseini D, et al. The microbiome in preadolescent acne: Assessment and prospective analysis of the influence of benzoyl peroxide. Pediatr Dermatol. 2019;36:200-6.

Kawashima M, Nagare T, Doi M. Clinical efficacy and safety of benzoyl peroxide for acne vulgaris: Comparison between Japanese and Western patients. J Dermatol. 2016;44:1212–18.

Gold LS, Weiss J, Rueda MJ, Liu H, Tanghetti E. Moderate and severe inflammatory acne vulgaris effectively treated with single-agent therapy by a new fixed-dose combination adapalene 0.3 %/ benzoyl peroxide 2.5 % gel: a randomized, double-blind, parallel-group, controlled study. Am J Clin Dermatol. 2016;17:293–303.

Draelos ZD, Ertel K, Rom D. Five-day study to judge the short-term effect of a benzoyl peroxide 3% gel on acne lesions. J Cosmet Dermatol. 2016;15:350–7.

Gamble R, Dunn J, Dawson A, Petersen B, McLaughling L, Small A, et al. Topical Antimicrobial Treatment of Acne Vulgaris. Am J Clin Dermatol. 2012;13:141–52.

Valente Duarte de Sousa IC. Novel pharmacological approaches for the treatment of acne vulgaris. Expert Opin Investig Drugs. 2014;23:1389–410.

Sieber MA, Hegel JK. Azelaic Acid: Properties and Mode of Action. Skin Pharmacol Physiol. 2014;27: 9–17.

Pazoki-Toroudi H, Nilforoushzadeh MA, Ajami M, Jaffary F, Aboutaleb N, Nassiri-Kashani M et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutan Ocul Toxicol. 2011;30:286–91.

Leccia MT, Auffret N, Poli F, Claudel JP, Corvec S, Dreno B. Topical acne treatments in Europe and the issue of antimicrobial resistance. J Eur Acad Dermatol Venereol. 2015;29:1485–92.

Fox L, Csongrad C, Aucamp M, Du Plessis J, Gerber M. Treatment Modalities for Acne. Molecules. 2016;21:1063. doi: 10.3390/molecules21081063.

Keating GM. Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel. Am J Clin Dermatol. 2011;12: 407–20.

Gollnick H, Abanmi AA, Al-Enezi M, Al Hammadi A, Galadari I, Kibbi AG, et al. Managing acne in the Middle East: consensus recommendations. J Eur Acad Dermatol Venereol. 2017;31:4–35.

Eichenfield LF, Fowler JF, Fried RG, Friedlander SF, Levy ML, Webster GF. Perspectives on therapeutic options for acne: an update. Semin Cutan Med Surg. 2010;29: 13–16.

Newman, MD, Bowe, WP, Heughebaert C, Shalita AR. Therapeutic Considerations for Severe Nodular Acne. Am J Clin Dermatol. 2011;12:7–14.

Farrah G, Tan E. The use of oral antibiotics in treating acne vulgaris: a new approach. Dermatol Ther. 2016;29:377–84.

Bagatin E, Florez-White M, Arias-Gomez, M. I., Kaminsky A. Algorithm for acne treatment: Ibero-Latin American consensus. An Bras Dermatol. 2017;92:689–93.

Bienenfeld A, Nagler AR, Orlow SJ. Oral antibacterial therapy for acne vulgaris: an evidence-based review. Am J Clin Dermatol. 2017;18:469–90.

Dessinioti C, Katsambas A. Propionibacterium acnes and antimicrobial resistance in acne. Clin Dermatol. 2017;35:163–7.

Dumont-Wallon G, Moyse D, Blouin E, Dréno B. Bacterial resistance in French acne patients. Int J Dermatol. 2010;49:283–8.

On SC, Zeichner J. Isotretinoin updates. Dermatol Ther. 2013;26:377–89.

Rademaker M. Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us? Australas J Dermatol. 2012;54:157–62.

Sandoval LF, Hartel JK, Feldman SR. Current and future evidence-based acne treatment: a review. Expert Opin Pharmacother. 2013;15:173–92.

Nast A, Dréno B, Bettoli V, Degitz K, Erdmann R, Finlay AY, et al. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol. 2012;1:1-29.

Bauer LB, Ornelas JN, Elston DM, Alikhan A. Isotretinoin: controversies, facts, and recommendations. Expert Rev Clin Pharmacol. 2016;9:1435–42.

Brzezinski P, Borowska K, Chiriac A, Smigielski J. Adverse effects of isotretinoin: A large, retrospective review. Dermatol Ther. 2017;30:e12483.

Aslam I, Fleischer A, Feldman S. Emerging drugs for the treatment of acne. Expert Opin Emerg Drugs. 2014;20:91–101.

Katsambas AD, Dessinioti C. Hormonal therapy for acne: why not as first line therapy? facts and controversies. Clin Dermatol. 2010;28:17–23.

Tripathi SV, Gustafson CJ, Huang KE, Feldman SR. Side effects of common acne treatments. Expert Opin Drug Saf. 2012;12:39–51.

Husein-ElAhmed H. Management of acne vulgaris with hormonal therapies in adult female patients. Dermatol Ther. 2015;28:166–72.

Barros B, Thiboutot D. Hormonal therapies for acne. Clin Dermatol. 2017;35(2), 168–172.

Mwanthi M, Zaenglein AL. Update in the management of acne in adolescence. Curr Opin Pediatr. 2018;30:492-8.

Lakshmi C. Hormone therapy in acne. Indian J Dermatol Venereol Leprol. 2013;79:322.

Nguyen HL, Tollefson MM. Endocrine disorders and hormonal therapy for adolescent acne. Curr Opin Pediatr. 2017;29:455–65.

Bettoli V, Zauli S, Virgili A. Is hormonal treatment still an option in acne today? Br J Dermatol. 2015;172:37–46.

Bissonnette R, Poulin Y, Drew J, Hofland H, Tan J. Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study. J Am Acad Dermatol. 2017;76:33–9.

How to Cite
Esteves Caseiro Mendes de Freitas, T., & Cardoso da Cunha Velho, G. M. (2021). Pharmacological Therapies in Acne vulgaris. Journal of the Portuguese Society of Dermatology and Venereology, 79(2), 129-135.
Review Articles